By Fineline Cube 
Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced it has received marketing approval from the U.S. Food and Drug Administration (FDA) for Cypsedo (cipepofol) for the induction of general anesthesia in adults, marking a historic milestone as the first Chinese-developed intravenous anesthetic to gain approval in the United States.
Regulatory Milestone & Development Timeline
| Parameter | Detail |
|---|---|
| Company | Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) |
| Product | Cypsedo (cipepofol) – Category 1 intravenous anesthetic |
| FDA Approval | Induction of general anesthesia in adults |
| China Approval History | Initial approval December 2020 |
| Pediatric Expansion | Induction/maintenance in children/adolescents (September 2025) |
| Additional Indications | Fiberoptic bronchoscopy procedures, ICU sedation |
| Market Significance | First Chinese-developed IV anesthetic approved in US |
Product Profile & Clinical Applications
- Molecule: Cipepofol (Cypsedo) – novel intravenous anesthetic agent
- Classification: Category 1 innovative drug (Chinese regulatory designation)
- Current Approved Uses:
- Induction of general anesthesia (adults – US; adults/children – China)
- Fiberoptic bronchoscopy procedural sedation
- Intensive care unit (ICU) sedation
- Maintenance of general anesthesia (pediatric populations)
- Administration: Intravenous formulation for rapid onset and controlled depth
- Development Timeline: Over 5 years of clinical use and expansion in China prior to US approval
Market Context & Competitive Landscape
| Aspect | Analysis |
|---|---|
| US Anesthesia Market | Annual IV anesthetic market valued at $2.3 billion; dominated by propofol and etomidate |
| Propofol Limitations | Pain on injection, respiratory depression, formulation stability issues |
| Cypsedo Differentiation | Potential improved safety profile and tolerability based on Chinese clinical experience |
| Chinese Innovation Milestone | Represents growing capability of Chinese biopharma to develop globally competitive specialty pharmaceuticals |
| Hospital Formulary Adoption | FDA approval enables inclusion in US hospital anesthesia protocols and formularies |
Strategic Implications & Commercial Outlook
- Global Expansion Strategy: US approval validates Cypsedo’s quality and efficacy for international markets
- Pricing Advantage: Potential cost competitiveness versus established anesthetics while offering novel mechanism
- Manufacturing Scale-Up: Haisco likely to expand GMP manufacturing capacity to meet US demand
- Additional Indication Pathway: Success in adult induction supports potential US filings for pediatric and procedural sedation indications
- Partnership Opportunities: US commercialization may attract distribution or co-promotion partnerships with established anesthesia-focused companies
The FDA approval represents a significant achievement for Haisco, demonstrating that Chinese pharmaceutical innovation can meet the rigorous standards of the world’s most demanding regulatory authority and compete in the sophisticated US hospital pharmaceutical market.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, commercial expectations, and market adoption for Cypsedo. Actual results may differ due to risks including market competition, formulary acceptance, and commercial execution.-Fineline Info & Tech